Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 2 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Zealand Pharma A/S is currently managing 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 4 distinct examiners and 2 distinct art units. REYNOLDS, FRED H is the busiest examiner, holding 1 busiest examiner pending action. This 1 busiest examiner pending action represents 1 of the 4 pending office actions. The distribution across 2 distinct art units suggests that the company's pending applications are grouped into two main technical areas within the broader pharmaceutical field.
With 4 distinct examiners involved, the company is receiving feedback from multiple individuals, which may lead to different prosecution outcomes. Practitioners should note that the workload is evenly spread, as no single examiner is handling more than one of the 4 pending office actions. The concentration in 2 distinct art units indicates a focused but multi-faceted approach to their patent strategy. Having 4 distinct examiners across only 2 distinct art units means that multiple examiners are working within the same administrative groups, which could result in varying interpretations of similar technical subject matter.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (40%) |
| §112 only | 1 (20%) |
| Double-patenting + other | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REYNOLDS, FRED H | 1 | 33.0% | +39.2% |
| COFFA, SERGIO | 1 | 61.1% | +32.5% |
| JAUHARI, SACHI | 1 | 60.0% | +80.0% |
| KONOPELSKI SNAVEL, SARA ELIZABETH | 1 | 33.3% | +38.9% |
| BEANE, RANDALL L | 1 | 32.8% | +36.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17279691 | FORMULATIONS OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES | BEANE, RANDALL L | 29d |
| 18690028 | PROCESS FOR FORMULATING COMPOSITIONS COMPRISING GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES | REYNOLDS, FRED H | — |
| 18688026 | DOSAGE REGIME | COFFA, SERGIO | — |
| 18282566 | KV1.3 Blockers | JAUHARI, SACHI | — |
| 18037795 | Pharmaceutical Composition of GLP-1/GLP-2 Dual Agonists | KONOPELSKI SNAVEL, SARA ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1654 | 2 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18690028 | PROCESS FOR FORMULATING COMPOSITIONS COMPRISING GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES | REYNOLDS, FRED H | — | §102§103§112DP | Non-Final OA | — | Pending | Mar 07, 2024 |
| 18688026 | DOSAGE REGIME | COFFA, SERGIO | — | §103 | Final Rejection | — | Pending | Feb 29, 2024 |
| 18282566 | KV1.3 Blockers | JAUHARI, SACHI | 1654 | §112Other | Non-Final OA | — | Pending | Sep 18, 2023 |
| 18037795 | Pharmaceutical Composition of GLP-1/GLP-2 Dual Agonists | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §103DP | Final Rejection | — | Pending | May 19, 2023 |
| 17279691 | FORMULATIONS OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES | BEANE, RANDALL L | 1654 | §103 | Final Rejection | 29d | Pending | Mar 25, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial